It is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Aclidinium bromide : Aclidinium bromide is a long-acting anti-muscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical, in vitro as well as in vivo studies, prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of aclidinium bromide is predominantly a site-specific effect. Formoterol fumarate : Formoterol fumarate is a long-acting selective beta2-adrenergic receptor agonist (LABA) (beta 2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. The pharmacologic effects of beta 2-adrenoceptor agonist drugs, including formoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
For oral inhalation only. Should be taken by inhaler device. 400 mcg/12 meg, twice daily (One inhalation capsule in the morning and one in the evening ). Do not take more than one inhalation twice daily.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Most common adverse reactions (incidence 3% and more common than with placebo) include: upper respiratory tract infection and headache.
Use of a long-acting beta 2-adrenergic agonist (LABA), including formoterol fumarate, one of the active ingredients in this combination, without an inhaled corticosteroid is contraindicated in patients with asthma. Hypersensitivity to aclidinium bromide or formoterol fumarate or to any component of this product.
Use of other adrenergic by any route may potentiate the effect of Aclitol. Use with caution. Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. Diuretics: Electrocardiographic changes and/or hypokalemia associated with non-potassium sparing diuretics may worsen with concomitant beta2-agonists. Use with caution. Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of formoterol fumarate on cardiovascular system. Beta-blockers: Use with caution and only when medically necessary. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administrations of Aclitol with other anticholinergic-containing drugs.
Asthma-related death: Long-acting beta2-adrenergic agonists as monotherapy (without an inhaled corticosteroid) for asthma increase the risk of serious asthma-related events. Do not initiate in acutely deteriorating COPD or to treat acute symptoms. Do not use in combination with additional medicine containing a LABA because of risk of overdose. If paradoxical bronchospasm occurs, discontinue Aclitol and institute alternative therapy. Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus and ketoacidosis. Be alert to hypokalemia and hyperglycemia. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a physician immediately if symptoms occur. Worsening urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to consult a physician immediately if symptoms occur.